TQ-1001

TQ-1001 is an investigational in vivo CAR-T cell therapy being developed by TQ Therapeutics for the treatment of autoimmune diseases. It utilizes the company's proprietary EXiVO platform to genetically reprogram a patient's endogenous T cells directly within the body to express a chimeric antigen receptor (CAR) targeting the CD19 antigen. By targeting CD19, TQ-1001 aims to deplete pathogenic B cells, which are central to the progression of various autoimmune conditions. This in vivo approach is designed to circumvent the logistical complexities, high costs, and safety concerns (such as the need for lymphodepleting chemotherapy) associated with traditional ex vivo CAR-T cell manufacturing. TQ-1001 is currently in the IND-enabling stage of development.